Date: 2016-04-28
Type of information: Plant acquisition
Acquired company: Rentschler Biotechnologie's Adeno-Associated Virus (AAV) manufacturing platform
Acquiring company: Freeline Therapeutics (UK)
Amount: undisclosed
Terms: * On April 17, 2016, Freeline Therapeutics announced the acquisition of the Adeno-Associated Virus (AAV) manufacturing platform developed by Rentschler Biotechnologie GmbH. In conjunction with the acquisition, Freeline has also established operations in Munich to further its manufacturing technology and maintain its leadership position for best in class manufacturing processes for AAV. Dr Markus Hörer, previously Director of Virus-based Biologics at Rentschler, has joined Freeline as founder and head of Freeline GmbH and Freeline’s Chief Technology Officer (CTO).
Details: Freeline, based at the UCL Medical School, Royal Free Hospital, London, was launched in December 2015 with a £25 million Series A financing from Syncona. The Company’s next-generation AAV gene therapy platform; developed by Professor Amit Nathwani, Founder and Chief Scientific Officer of Freeline as well as Professor of Haematology at University College London, builds on the successful haemophilia B phase I/II trial conducted by him with St. Jude Children’s Research Hospital.
Related: Manufacturing Production Gene therapy
